SCHEMBL6008269

SCHEMBL6008269

c1nc2cc(-c3ccc4[nH]cnc4c3)ccc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
APEX1 P27695 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
QPCT Q16769 6/20 0.49
QPCTL Q9NXS2 4/20 0.49
PRKCI P41743 2/20 0.47
RAD52 P43351 1/20 0.45
MMP12 P39900 1/20 0.42
CYP3A4 P08684 1/20 0.41
NAMPT P43490 1/20 0.41
XDH P47989 1/20 0.41
BRD4 O60885 1/20 0.41
CREBBP Q92793 1/20 0.41
ACVR1 Q04771 1/20 0.41
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2474515 0.92 QPCT (0.60) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL2457365 0.90 QPCT (0.50) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL13373351 0.88 ALDH1A1 (0.46) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL13373486 0.88 PARP1 (0.46) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL28178019 0.88 PSMD11 (0.49) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL7021134 0.88 QPCT (0.49) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL28178021 0.88 PARP1 (0.46) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL25912038 0.88 PARP1 (0.46) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL23123086 0.87 QPCT (0.51) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL22418755 0.87 QPCT (0.47) MAPTKDM4EALDH1A1APEX1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102177141-B bis-1H-benzimidazoles as hepatitis C virus inhibitors BRISTOL MYERS SQUIBB CO 2014-07-23 CN claimed
EP-2575968-A1 COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE Summit Corporation Plc (GB) 2013-04-10 EP claimed
WO-2011151621-A1 COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE SUMMIT CORPORATION PLC (GB) 2011-12-08 WO claimed
EP-4277604-A1 SOLID TABLET DOSAGE FORM OF RIDINILAZOLE Summit (Oxford) Limited (GB) 2023-11-22 EP disclosed
WO-2022153246-A1 SOLID TABLET DOSAGE FORM OF RIDINILAZOLE SUMMIT (OXFORD) LTD. (GB) 2022-07-21 WO disclosed
CN-112274481-A Pantoprazole sodium composition for injection and preparation method thereof 海南卫康制药(潜山)有限公司 2021-01-29 CN disclosed
CN-108623806-B Polybenzimidazole with side ammonium groups, anion exchange membrane thereof and preparation method thereof 大连理工大学 2020-08-25 CN disclosed
EP-3011960-B1 COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE SUMMIT THERAPEUTICS PLC (GB) 2020-04-15 EP disclosed
EP-2459545-B1 EPOXIDATION PROCESS SOUTH BANK UNIV ENTERPRISES LIMITED (GB) 2019-03-27 EP disclosed
CN-108026670-A Phosphorylated PBI fibers PBI性能产品公司 2018-05-11 CN disclosed
CN-105377950-B Process for preparing polybenzimidazole PBI性能产品公司 2017-12-29 CN disclosed
EP-2481119-A1 PROTON EXCHANGE MEMBRANE COMPRISING POLYMER BLENDS FOR USE IN HIGH TEMPERATURE PROTON EXCHANGE MEMBRANE FUEL CELLS EWE-Forschungszentrum Für Energietechnologie E.V. (DE) 2012-08-01 EP disclosed
EP-2459545-A2 PROCESS South Bank University Enterprises Limited (GB) 2012-06-06 EP disclosed
US-20120136165-A1 PROCESS SOUTH BANK UNIVERSITY ENTERPRISES LTD. (GB) 2012-05-31 US disclosed
WO-2011151618-A2 COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE SUMMIT CORPORATION PLC (GB) 2011-12-08 WO disclosed
WO-2011012869-A2 PROCESS SOUTH BANK UNIVERSITY ENTERPRISES LTD (GB) 2011-02-03 WO disclosed
EP-1719200-A2 HIGH-PERFORMANCE MEMBRANE ELECTRODE UNIT AND THE USE THEREOF IN FUEL CELLS Pemeas GmbH (DE) 2006-11-08 EP disclosed
WO-2005081351-A2 HIGH-PERFORMANCE MEMBRANE ELECTRODE UNIT AND THE USE THEREOF IN FUEL CELLS PEMEAS GMBH (DE) 2005-09-01 WO disclosed
EP-0511187-B1 Process for the preparation of 1H-benzimidazoles UCB SA (BE) 1996-11-20 EP disclosed
EP-0511187-A1 Process for the preparation of 1H-benzimidazoles U C B, S.A. (BE) 1992-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136165-A1 PROCESS AOX1, NOX4, SMOX MAPT 3597/4885KDM4E 551/4885ALDH1A1 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.